Affiliation:
1. University of Utah. College of Pharmacy. Department of Pharmacotherapy. SLC, Utah
2. Àrea del Medicament i Servei de Farmàcia, Gerència d'Atenció Primària Barcelona Ciutat, Insitut Català de la Salut, Barcelona
3. Fundació Institut Universitari per a la Recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona
4. Marketing farmacéutico & Investigación clínica, Barcelona
5. Servei d’Atenció Primaria Barcelonés Nord i Maresme. Badalona, Barcelona
Abstract
Abstract
Background: Exposure to medicines during pregnancy is frequent, even more during first trimester as pregnant women might not be aware of their condition. Aiming to establish potential relationship of earlier exposure to medicines and risk of abortion we conducted an observational study.
Methods: this is a retrospective case-control study of abortions (cases) and live birth pregnancies (controls) matched by mother age using SIDIAP database (Catalan Primary Health electronic health records database). Exposure to medicines while pregnant was considered to assess the risk of abortion during the first trimester. The odds ratio was estimated by a conditional logistic regression and adjust by health conditions and medicines exposures.
Results: A total of 60,350 episodes of abortions were matched to 118,085 live birth/completed pregnancy episodes. Cases had higher rates of alcohol intake (9.9% vs 7.2%), smoking (4.5% vs 3.6%) and of previous abortions (9.9% vs 7.8%). Anxiety (30.3% and 25.1%), respiratory diseases (10.6% and 9.2%) and migraine (8.2% and 7.3%), for cases and controls respectively, were the most frequent baseline conditions. Cases had higher rate of exposure to medicines [40,148 (66.5%) vs 37636 (68.9%), p<0.001, cases and controls respectively]. A risk for abortion was found for antihistamines for systemic use (ORadj 1.23, 95%CI 1.19-1.27), antidepressants (ORadj 1.11, 95%CI 1.06-1.17), anxiolytics (ORadj 1.31, 95%CI 1.26-1.73), and anti-inflammatory and rheumatic products, non-steroids (ORadj 1. 63, 95%CI 1.59-1.67).
Conclusions: These highest rate of medicines exposures during the first trimester of pregnancy and their relationship with abortion highlights the relevance of prescription to women with childbearing potential and may lead to better family planning information and contraception plans.
Registration: EUPAS37675
Publisher
Research Square Platform LLC
Reference58 articles.
1. Prenatal exposure to teratogenic medications in the era of Risk Evaluation and Mitigation Strategies;Sarayani A;Am J Obstet Gynecol,2022
2. Centers for Disease Control and Prevention. Treating for Two: Medicine and Pregnancy: Guidelines and Recommendations for Treating and Managing Health Conditions during Pregnancy. CDC; 2022. Accessed July 27, 2022. https://www.cdc.gov/pregnancy/meds/treatingfortwo/treatment-guidelines.html.
3. The French Pregnancy Cohort: Medication use during pregnancy in the French population;Bérard A;PLoS ONE,2019
4. La cohorte des grossesses du Québec: prévalences et conséquences de l’utilisation des médicaments durant la grossesse;Bérard A;Therapies,2014
5. Evolving knowledge of the teratogenicity of medications in human pregnancy;Adam MP;Am J Med Genet Part C: Seminars Med Genet,2011